my country's first anti -new crown oral medicine is here!

Azfdin, who has been approved for more than two years of phase III clinical trials, is expected to become my country's first oral anti -new crown drug with completely independent intellectual property rights!

On July 15th, Henan Real Biotechnology Co., Ltd. (hereinafter referred to as "real creature") announced that it has officially submitted a listing application for the treatment of new coronary virus indications to the National Drug Administration for the treatment of new coronary virus.

Since April 2020, Azf has been approved at home and abroad to conduct phase III clinical trials. The clinical trial results show:

Significant improvement of clinical symptoms. Azf's fixed tablet can significantly shorten the moderate new type of coronary virus infection with pneumonia patients, the proportion of patients with improvement of clinical symptoms, and achieve clinical excellent results. On the first 7th day of the administration, the proportion of the subjects of the clinical symptoms improved 40.43%, and the placebo group was 10.87%(P value <0.001). There are very significant statistical differences with the placebo group (P value <0.001).

Inhibit the role of new coronal virus. Azf has the activity of inhibiting the new coronary virus, and the virus clearance time is about 5 days.

In terms of safety. The overall tolerance of Azf's fixed film is good, and the incidence of adverse events has no statistical differences with the placebo group, and the risk of the subject has not increased.

It is understood that Azf is the world's first double -target anti -AIDS innovation medicine, and has applied for patents in many countries such as China, the United States and other countries. As a antivirus small molecule oral medication, Azf has a broad -spectrum to inhibit the replication of RNA virus, while the new coronal virus belongs to RNA as a hereditary virus, so the medicine has inhibitory effects on the new crown virus.

Dr. Du Jinfa, the chief scientist of the real biology, said: "We are very happy to usher in this important moment. I look forward to Azf's early approval and provide a force for the prevention and control of domestic and global epidemic conditions."

Azf's drug inventor, former president of Henan Normal University, now said that "Azfding is a nucleoside of RNA -dependent RNA polymerase (RDRP) of virus RNA polymers (RDRP) Things, the specificity can act on the new coronary virus RDRP, thereby inhibiting virus replication, and its drug is targeted. "

Jiang Jiandong, an academician of the Chinese Academy of Engineering and the dean of the Beijing Academy of Pharmaceutical Research, Chinese Academy of Medical Sciences, said: "Azf has obvious anti -new coronal virus effects, which is effective for patients with clinical enlightening. The new crown of mechanism, this is its distinctive biological characteristics. "

Original title: my country's first anti -new crown oral medication is here

■ Source: Henan Provincial People's Government official website, Henan Daily client

■ Yue Xun finishing

- END -